TTM Technologies, Inc.’s $152 Million Secondary Offering of Common Stock

Davis Polk advised Su Sih (BVI) Limited as the selling stockholder in connection with an SEC-registered secondary offering of 13,800,000 shares of TTM Technologies, Inc.’s common stock. The total net proceeds to the selling stockholder from the offering were approximately $152 million. TTM Technologies is a leading global printed circuit board, or PCB, manufacturer, focusing […]

CDH Investments’ $800 million placing of shares in WH Group

Paul Hastings represented Chinese private equity investor CDH Investments (“CDH”) in its US$800 million (HK$6.25 billion) placing of shares in WH Group, the world’s largest pork producer and processor. Morgan Stanley acted as the placing agent. The Paul Hastings team was led by Raymond Li (Picture), partner and Chair of Greater China, and partner Vivian […]

Going-Private Transaction of KongZhong

Davis Polk is advising the buyer group consisting of Mr. Leilei Wang, Gongqingcheng Wujiang Xingyao Investment Management Partnership (Limited Partnership), Hexie Chengzhang Phase II (Yiwu) Investment Center (Limited Partnership) and some of their affiliates in connection with the going-private transaction of KongZhong Corporation. Mr. Leilei Wang is the chairman and chief executive officer of KongZhong. […]

Acushnet’s $378 Million Initial Public Offering

Simpson Thacher represented Acushnet Holdings Corp. (“Acushnet”) in connection with the initial public offering of 22,233,332 shares of its common stock. The shares began trading on the New York Stock Exchange on October 28, 2016, under the ticker symbol “GOLF.” All 22,233,332 shares of common stock sold in the offering were sold by existing stockholders […]

Zhou Hei Ya International Holdings’ $321.8 Million Hong Kong Initial Public Offering

Simpson Thacher represented Zhou Hei Ya International Holdings Company Limited (“Zhou Hei Ya”) in connection with its initial public offering in Hong Kong and Rule 144A/Regulation S offering of an aggregate of 424,470,000 shares (prior to any exercise of the overallotment option), which raised approximately HK$2,495.9 million (US$321.8 million) in gross proceeds. The ordinary shares […]

The Export-Import Bank of Korea’s $200 Million Notes Offering

Davis Polk advised the underwriter in connection with an SEC-registered Schedule B debt offering by KEXIM of $200 million aggregate principal amount of its floating-rate notes due 2018. Goldman Sachs International acted as Sole Bookrunner and Lead Manager. KEXIM is an official export credit agency providing comprehensive export credit and guarantee programs to support Korean […]

Taikang Insurance’s $168 Million acquisition of interest in Harmonicare

Paul Hastings LLP advised Taikang Insurance Group Inc. on the acquisition of a 26.44% stake in Harmonicare Medical Holdings Limited, a company listed on the Hong Kong Stock Exchange and the largest private obstetrics and gynecology specialty hospital group in the PRC. Taikang is a leading innovative insurance and financial service group in the PRC, […]

JNBY Design Limited’s $103.2 Million Initial Public Offering and Regulation S Offering

Simpson Thacher represented JNBY Design Limited (“JNBY”) in connection with its initial public offering in Hong Kong and Regulation offering of an aggregate of 125,000,000 shares (prior to the exercise of the overallotment option), which raised HK$800 million (approximately US$103.2 million) in gross proceeds. The shares of JNBY are listed on the Hong Kong Stock […]

Origin Agritech Limited’s Sale of Commercial Seed Production and Distribution Business

Davis Polk is advising the special committee of the board of directors of Origin Agritech Limited in connection with the sale of its commercial corn seed production and distribution assets located in the PRC to Beijing Shihui Agricultural Development Co., Limited, a company controlled by the brother of the chairman of Origin’s board of directors. […]

JHL Biotech Inc.’s strategic alliance with Sanofi for the development and commercialization of biosimilar therapies in China

A Ropes & Gray cross-practice and cross-office team advised JHL Biotech Inc. on a landmark strategic alliance with global healthcare leader Sanofi, which involves the development and commercialization of biosimilar therapies in China using JHL’s development and manufacturing facilities in Taiwan and China, and Sanofi’s commercial sales platform in China. The transaction, valued at $337 […]